Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease ; volume:9 ; number:1 ; day:30 ; month:10 ; year:2023 ; pages:1-11 ; date:12.2023
npj Parkinson's Disease ; 9, Heft 1 (30.10.2023), 1-11, 12.2023
- Urheber
-
Diaw, Sokhna Haissatou
Borsche, Max
Streubel-Gallasch, Linn
Dulovic-Mahlow, Marija
Hermes, Julia
Lenz, Insa
Seibler, Philip
Klein, Christine
Brüggemann, Norbert
Vos, Melissa
Lohmann, Katja
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-023-00584-z
- URN
-
urn:nbn:de:101:1-2024011708362395981447
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Diaw, Sokhna Haissatou
- Borsche, Max
- Streubel-Gallasch, Linn
- Dulovic-Mahlow, Marija
- Hermes, Julia
- Lenz, Insa
- Seibler, Philip
- Klein, Christine
- Brüggemann, Norbert
- Vos, Melissa
- Lohmann, Katja
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
Models of α-synuclein aggregation in Parkinson’s disease
α-Synuclein in parkinson's disease: pathogenic function and translation into animal models
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
Models of α-synuclein aggregation in Parkinson’s disease
α-Synuclein in parkinson's disease: pathogenic function and translation into animal models
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
Models of α-synuclein aggregation in Parkinson’s disease
α-Synuclein in parkinson's disease: pathogenic function and translation into animal models
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models